Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Coyle, Douglas
Davies, Linda
and
Drummond, Michael F.
1998.
Trials and Tribulations:Emerging Issues in Designing Economic Evaluations Alongside Clinical Trials.
International Journal of Technology Assessment in Health Care,
Vol. 14,
Issue. 1,
p.
135.
Drummond, Michael F.
1998.
Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals.
Medical Decision Making,
Vol. 18,
Issue. 2_suppl,
p.
S12.
Johnson, Jeffrey A.
Connolly, Melinda A.
Jacobs, Philip
Montgomery, Mark
Brown, Neil E.
and
Zuberbuhler, Peter
1999.
Cost of Care for Individuals with Cystic Fibrosis: A Regression Approach to Determining the Impact of Recombinant Human DNase.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
Vol. 19,
Issue. 10,
p.
1159.
Schrogie, John J.
1999.
Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
American Heart Journal,
Vol. 137,
Issue. 5,
p.
S126.
Edbrooke, David L.
and
Hibbert, Clare L.
1999.
Cost determinants and economic assessment in the critical care setting.
Current Opinion in Critical Care,
Vol. 5,
Issue. 4,
p.
316.
Dixon, Simon
Deverill, Mark
Gannon, Mary
Brazier, John
and
Haggard, Mark
1999.
Improving the Validity of Economic Evaluations Alongside Controlled Trials.
Journal of Health Services Research & Policy,
Vol. 4,
Issue. 3,
p.
161.
Estrada, Carlos A.
Mansfield, Christopher J.
and
Heudebert, Gustavo R.
2000.
Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis.
Journal of General Internal Medicine,
Vol. 15,
Issue. 2,
p.
108.
Wong, John B.
Poynard, Thierry
Ling, Mei-Hsiu
Albrecht, Janice K.
and
Pauker, Stephen G.
2000.
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c.
The American Journal of Gastroenterology,
Vol. 95,
Issue. 6,
p.
1524.
Evans, Christopher
and
Crawford, Bruce
2000.
Direct Medical Costing for Economic Evaluations: Methodologies and Impact on Study Validity.
Drug Information Journal,
Vol. 34,
Issue. 1,
p.
173.
McCabe, Chris
and
Dixon, Simon
2000.
Testing the Validity of Cost-Effectiveness Models.
PharmacoEconomics,
Vol. 17,
Issue. 5,
p.
501.
Gould, A. Lawrence
2001.
BIOPHARMACEUTICAL STATISTICS BEYOND 2000.
Journal of Biopharmaceutical Statistics,
Vol. 11,
Issue. 1-2,
p.
1.
Pronovost, Peter
and
Angus, Derek C.
2001.
Economics of end-of-life care in the intensive care unit.
Critical Care Medicine,
Vol. 29,
Issue. Supplement,
p.
N46.
Uc, Ergun Y.
DeLeo, Andrea J.
and
Rodnitzky, Robert L.
2001.
Clinical Trials in Neurologic Practice.
Vol. 25,
Issue. ,
p.
173.
Pang, Francis
2002.
Design, Analysis and Presentation of Multinational Economic Studies.
PharmacoEconomics,
Vol. 20,
Issue. 2,
p.
75.
Raisch, Dennis W
Netravali, Shalaka S
and
Harris, Crystal L
2003.
Pharmacoeconomic Implications of Large Multicenter Clinical Trials.
Annals of Pharmacotherapy,
Vol. 37,
Issue. 3,
p.
447.
Soto Álvarez, Javier
2003.
Inclusión de análisis farmacoeconómicos en ensayos clínicos: principios y prácticas.
Medicina Clínica,
Vol. 120,
Issue. 6,
p.
227.
Torrance, George W.
Drummond, Michael F.
and
Walker, Valery
2003.
Switching Therapy in Health Economics Trials: Confronting the Confusion.
Medical Decision Making,
Vol. 23,
Issue. 4,
p.
335.
O'Sullivan, Amy K.
Thompson, David
and
Drummond, Michael F.
2005.
Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future for Piggyback Evaluations?.
Value in Health,
Vol. 8,
Issue. 1,
p.
67.
Simoens, Steven
and
Laekeman, Gert
2005.
Applying health technology assessment to pharmaceutical care: pitfalls and future directions.
Pharmacy World & Science,
Vol. 27,
Issue. 2,
p.
73.
Swan Tan, Siok
Bouwmans-Frijters, Clazien A. M.
and
Hakkaart-van Roijen, Leona
2012.
Handleiding voor kostenonderzoek: methoden en referentieprijzen voor economische evaluaties in de gezondheidszorg.
Tijdschrift voor gezondheidswetenschappen,
Vol. 90,
Issue. 6,
p.
367.